The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data-Reference-Cited by-同舟云学术

The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data

Published:2015-06-08 Issue:7 Volume:36 Page:841-846
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Gu Jie-mei,Wang Li,Lin Hua,Chen De-cai,Tang Hai,Jin Xiao-lan,Xia Wei-bo,Hu Yun-qiu,Fu Wen-zhen,He Jin-wei,Zhang Hao,Wang Chun,Yue Hua,Hu Wei-wei,Liu Yu-juan,Zhang Zhen-lin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/aps201530.pdf

Reference12 articles.

1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52.

2. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91.

3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40.

4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103–11.

5. McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int 2013; 24: 293–9.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women;Cochrane Database of Systematic Reviews;2022-05-03

2. Development of UV Spectrophotometric Methods for the Determination of Risedronate Sodium in Different Solutions;Journal of Applied Spectroscopy;2021-11

3. Physicians’ Attitudes on Management of Osteopenia in South Korea;Journal of Bone Metabolism;2020-08-31

4. Alterations in DNA methylation profiles in cancellous bone of postmenopausal women with osteoporosis;FEBS Open Bio;2020-06-26

5. Searching for valuable differentially expressed miRNAs in postmenopausal osteoporosis by RNA sequencing;Journal of Obstetrics and Gynaecology Research;2020-05-19